Aspire BioPharma, Inc. — Form C (Regulation Crowdfunding)
Aspire BioPharma, Inc. of HUMACAO, PR filed a Form C (Regulation Crowdfunding) with the SEC on 2023-10-31. Target raise $150K, up to $5.0M. Offered through OpenDeal Portal LLC.
Offering
- Filed: 2023-10-31
- Form: C
- Accession: 0001995528-23-000001
- Target amount: $150K
- Maximum amount: $5.0M
- Security type: Preferred Stock
- Securities offered: 187,500
- Price: $0.8000
- Deadline: 2024-01-31
- Funding portal / intermediary: OpenDeal Portal LLC
- Intermediary file number: 007-00167
- Intermediary CRD: 283874
Issuer
- CIK: 0001995528
- Website: https://aspirebiolabs.com
- Legal status: Corporation
- Organized in: PR
- Incorporated: 2021-09-27
- Address: 194 CANDELERO DRIVE, HUMACAO, PR, 00791
- Employees: 0
Financials (as filed)
- Total assets (most recent): $4.9M
- Cash (most recent): $38
- Net income (most recent): $-597K
- Net income (prior): $-464K
- Short-term debt: $194K
- Long-term debt: $3.9M
People (3)
| Name | Role | Location |
|---|
| Stephen Quesenberry | General Counsel and Corporate Secretary | salem, UT |
| Ernest J. Scheidemann | Chief Financial Officer | Humacao, PR |
| Kraig T. Higginson | Chief Executive Officer & Chairman of the Board | Humacao, PR |
Reg CF filing history (3)
More